Fact checked byDrew Amorosi

Read more

November 04, 2024
2 min read
Save

Top in cardiology: Benefits of colchicine refuted; valve replacement for aortic stenosis

Fact checked byDrew Amorosi
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Patients referred for percutaneous coronary intervention after acute myocardial infarction did not experience improved cardiovascular outcomes when taking colchicine compared with placebo, refuting previous study results.

Healio previously reported that colchicine reduced risk for cardiovascular death, resuscitated cardiac arrest, MI, stroke or hospitalization for angina in the COLCOT trial of 4,745 adults. However, according to new data from the CLEAR SYNERGY (OASIS-9) trial presented at the 2024 Transcatheter Cardiovascular Therapeutics Conference, adults who underwent randomization within 72 hours of percutaneous coronary intervention after acute heart attack experienced no difference in heart-related outcomes compared to placebo.

Someone clutching heart
Patients referred for percutaneous coronary intervention after acute myocardial infarction did not experience improved cardiovascular outcomes taking colchicine compared with placebo. Image: Adobe Stock

It was the top story in cardiology last week.

In another top story, patients with asymptomatic severe aortic stenosis who received a transcatheter aortic valve replacement had better cardiovascular outcomes compared with those who received routine clinical surveillance.

Read these and more top stories in cardiology below:

Colchicine does not improve outcomes in patients getting PCI after acute heart attack

Contradicting previous research, in a large trial of patients referred for percutaneous coronary intervention after acute myocardial infarction, colchicine did not improve cardiovascular outcomes compared with placebo, according to data from the CLEAR SYNERGY (OASIS-9) trial presented at the 2024 Transcatheter Cardiovascular Therapeutics

Conference. Read more.

Early TAVR bests surveillance in patients with asymptomatic severe aortic stenosis

Among patients with asymptomatic severe aortic stenosis, those who had transcatheter aortic valve replacement had better cardiovascular outcomes compared with those who had routine clinical surveillance, results of the EARLY TAVR trial showed. Read more.

Real-world data links low-dose aspirin use to increased anemia risk among older adults

Low-dose aspirin use corresponded with an increased risk for anemia among older Danish adults in a real-world setting, according to a study published in European Heart Journal – Quality of Care and Clinical Outcomes. Read more.

TAVR for moderate aortic stenosis, HFrEF may improve quality of life

In patients with moderate aortic stenosis and heart failure with reduced ejection fraction, transcatheter aortic valve replacement did not improve clinical outcomes but may raise quality of life vs. clinical surveillance, data show. Read more.

‘Obesity is the new hypertension’: The current landscape of pharmacological weight loss

After decades of research, pharmacologic treatment of obesity gained significant traction with the launch of GLP-1 receptor agonists, and several potentially more potent drugs are currently in the pipeline, a speaker at the Cardiometabolic Health Congress reported. Read more.